The role of soluble urokinase plasminogen activator receptor as an early biomarker of severity and organ failure in patients with acute pancreatitis

Author(s):  
Amir Soleimani
2018 ◽  
Vol 48 (6) ◽  
pp. 1175-1181
Author(s):  
Kadir KÜÇÜKCERAN ◽  
Mehmet ERGİN ◽  
İbrahim KILINÇ ◽  
Adnan KARAİBRAHİMOĞLU ◽  
Tamer ÇOLAK ◽  
...  

Blood ◽  
2010 ◽  
Vol 116 (9) ◽  
pp. 1593-1603 ◽  
Author(s):  
Brian M. Connolly ◽  
Eun Young Choi ◽  
Henrik Gårdsvoll ◽  
Alexandra L. Bey ◽  
Brooke M. Currie ◽  
...  

The urokinase plasminogen activator receptor (uPAR) has emerged as a potential regulator of cell adhesion, cell migration, proliferation, differentiation, and cell survival in multiple physiologic and pathologic contexts. The urokinase plasminogen activator (uPA) was the first identified ligand for uPAR, but elucidation of the specific functions of the uPA-uPAR interaction in vivo has been difficult because uPA has important physiologic functions that are independent of binding to uPAR and because uPAR engages multiple ligands. Here, we developed a new mouse strain (PlauGFDhu/GFDhu) in which the interaction between endogenous uPA and uPAR is selectively abrogated, whereas other functions of both the protease and its receptor are retained. Specifically, we introduced 4 amino acid substitutions into the growth factor domain (GFD) of uPA that abrogate uPAR binding while preserving the overall structure of the domain. Analysis of PlauGFDhu/GFDhu mice revealed an unanticipated role of the uPA-uPAR interaction in suppressing inflammation secondary to fibrin deposition. In contrast, leukocyte recruitment and tissue regeneration were unaffected by the loss of uPA binding to uPAR. This study identifies a principal in vivo role of the uPA-uPAR interaction in cell-associated fibrinolysis critical for suppression of fibrin accumulation and fibrin-associated inflammation and provides a valuable model for further exploration of this multifunctional receptor.


2019 ◽  
Vol 40 (8) ◽  
pp. 947-955 ◽  
Author(s):  
Sven H Loosen ◽  
Frank Tacke ◽  
Niklas Püthe ◽  
Marcel Binneboesel ◽  
Georg Wiltberger ◽  
...  

Abstract Surgical resection represents the only potentially curative therapy for patients with pancreatic adenocarcinoma (PDAC), an aggressive malignancy with a very limited 5-year survival rate. However, even after complete tumor resection, many patients are still facing an unfavorable prognosis underlining the need for better preoperative stratification algorithms. Here, we explored the role of the secreted glycoprotein soluble urokinase plasminogen activator receptor (suPAR) as a novel circulating biomarker for patients undergoing resection of PDAC. Serum levels of suPAR were measured by enzyme-linked immunosorbent assay (ELISA) in an exploratory as well as a validation cohort comprising a total of 127 PDAC patients and 75 healthy controls. Correlating with a cytoplasmic immunohistochemical expression of uPAR in PDAC tumor cells, serum levels of suPAR were significantly elevated in PDAC patients compared to healthy controls and patient with PDAC precursor lesions. Importantly, patients with high preoperative suPAR levels above a calculated cutoff value of 5.956 ng/ml showed a significantly reduced overall survival after tumor resection. The prognostic role of suPAR was further corroborated by uni- and multivariate Cox-regression analyses including parameters of systemic inflammation, liver and kidney function as well as clinico-pathological patients’ characteristics. Moreover, high baseline suPAR levels identified those patients particularly susceptible to acute kidney injury and surgical complications after surgery. In conclusion, our data suggest that circulating suPAR represents a novel prognostic marker in PDAC patients undergoing tumor resection that might be a useful addition to existing preoperative stratification algorithms for identifying patients that particularly benefit from extended tumor resection.


Sign in / Sign up

Export Citation Format

Share Document